Mean total and hormone sensitive spending during the intervention phases of the CEE+MPA trial (median follow 5.1 years) and the CEE-alone trial (median follow-up 6.7 years). The global index spending includes coronary heart disease, invasive breast cancer, pulmonary embolism, stroke, colorectal cancer, hip fracture and, for the CEE+MPA trial, endometrial cancer.